China approves world’s first inhaled Covid vaccine for emergency use

Vaccine maker CanSino Biologics said: statement China’s drug regulator approved an inhaled dose for emergency use as a booster vaccine Sunday.

The product, known as Convidecia Air, delivers the vaccine with a puff of air from a nebulizer, which is then inhaled by mouth. CanSino’s injected Convidecia Covid-19 vaccine is already in use in China and has been approved in several other countries.

according to database Regulated by the World Health Organization (WHO), CanSino’s new product is one of two special “inhaled” vaccines that have reached clinical stage development, and is being administered by many companies around the world through the nose and mouth. researching innovative ways to provide Covid-19 protection.

The inhalation shot clearance comes as multiple Chinese cities implement massive Covid lockdowns and massive test drives in response to smaller outbreaks.

The country continues to adhere to a strict zero Covid policy even as the rest of the world learns to live with the virus.

More than 70 cities in China have been under and affected by full or partial Covid lockdowns since late August over 300 millionaccording to a CNN tally.

Low vaccination coverage among the elderly is one of the medical reasons used by Chinese authorities to justify ongoing disease control measures.

Meanwhile, a new variant of the coronavirus could affect the protection provided by first-generation vaccines around the world, including a Chinese homegrown vaccine that does not offer robust antibody protection compared to Western-developed mRNA vaccines. I am giving

Booster and vaccine campaigns and next-generation product development are underway in China.

It remains unclear what part of this situation a new inhaled vaccine will fill. company filing He said some regulatory measures remained before the vaccine could hit the market, and said the product would face “intense competition” domestically. Nine vaccines have been licensed so far.
and news releaseCanSino says Convidecia Air “can induce potent humoral, cellular and mucosal immunity.”

The manufacturer does not provide any data to support these claims, but cites research in The Lancet medical journal.

In a small study published in August, CanSino researchers reported that an inhaled vaccine booster increased antibody levels compared to a third CoronaVac injection in people who received two injections of the CoronaVac vaccine. Did.

Developed by Beijing-based Sinovac, which is widely used in China and around the world, Coronavac uses a different type of technology than Combidesia, so inhaled doses provide heterogeneous or combined boosts. did.

The study did not test whether inhaled doses would prevent people from getting infected or transmitting Covid to others.

Globally, drug makers are racing to produce next-generation vaccines that could improve protection against Covid, including those that use innovative methods of administration.

Clinical trials are underway to test more than a dozen spray vaccines to see if they can create so-called mucosal immunity. It enhances specific antibodies in the mouth.

Administered by mouth or nose as drops, sprays, or tablets, these non-shot vaccines are also expected to prevent human-to-human spread. A new variant of the virus.

CanSino’s Convidecia vaccine is similar to Johnson & Johnson and Oxford AstraZeneca vaccines. It uses a harmless virus called adenovirus to make Covid’s spike proteins into your cells so your body can make antibodies against them.

None of CanSino’s products are approved for use in the United States, but the World Health Organization earlier this year listed an injectable version of Conbidesia for emergency use.


Scroll to Top